Emerging applications of gene edited T cells for the treatment of leukemia.

about

X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective.Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?

P2860

Q52579140-5C6E3494-C11D-46DE-B6DA-49C3143D6600 Q55292778-65DB44E8-4FF7-4762-817D-EED16BDD543A

P2860

Emerging applications of gene edited T cells for the treatment of leukemia.

Item

http://www.wikidata.org/entity/Q50029336

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Emerging applications of gene edited T cells for the treatment of leukemia.

@en

Emerging applications of gene edited T cells for the treatment of leukemia.

@nl

type

Item

label

Emerging applications of gene edited T cells for the treatment of leukemia.

@en

Emerging applications of gene edited T cells for the treatment of leukemia.

@nl

prefLabel

Emerging applications of gene edited T cells for the treatment of leukemia.

@en

Emerging applications of gene edited T cells for the treatment of leukemia.

@nl

P1476

Emerging applications of gene edited T cells for the treatment of leukemia.

@en

P2860

megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering.

The basic principles of chimeric antigen receptor design.

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.

Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.

RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.

P304

753-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1080/17474086.2017.1350575

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Waseem Qasim

Christos Georgiadis

P577

2017-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28675317

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

Emerging applications of gene edited T cells for the treatment of leukemia.

about

P2860

P2860

Emerging applications of gene edited T cells for the treatment of leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921